This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petros, W. P. Articles by Peters, W. P. Search for Related Content PubMed PubMed Citation Articles by Petros, W. P. Articles by Peters, W. P.

Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer¹

Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27710

This report investigates relationships between the pharmacokinetics and pharmacodynamics of high-dose alkylators used for the treatment of primary breast cancer.

Eighty-five women with primary breast cancer involving 10 lymph nodes received four cycles of standard-dose chemotherapy followed by a high-dose regimen consisting of: cyclophosphamide (1875 mg/m² once daily x 3), cisplatin (165 mg/m² given over 72 h), carmustine (600 mg/m²), and stem cell transplantation. Dosages were attenuated in patients whose body weight exceeded their calculated ideal weight by >20%. Pharmacokinetics of the high-dose chemotherapeutic agents were evaluated in each patient by collection and analysis of serial blood samples.

Area under the concentration time curve (AUC) for cyclophosphamide and carmustine was highly variable (>10-fold inter-patient range) with coefficients of variation > 50%, in contrast to cisplatin exposures (2-fold range; coefficient of variation 12%). The dosing method for overweight patients resulted in significantly lower systemic exposure to cisplatin (P = 0.035). The parent cyclophosphamide clearance on the 1st day of administration was significantly higher in patients who experienced acute cardiac toxicity (n = 5; P = 0.011), whereas carmustine disposition was not found to be different in those developing pulmonary toxicity (n = 25; P = 0.96). Kaplan-Meier analysis (median follow-up of 5.9 years) demonstrated that patients with lower cyclophosphamide AUC (faster parent drug clearance to potentially cytotoxic compounds) survived longer (P = 0.031).

Inter-individual differences in the pharmacokinetic disposition of high-dose chemotherapy may explain variability in both response and toxicity. Prospective strategies, which attempt to individualize AUC, should be evaluated in this setting.

This article has been cited by other articles:

				W. P. Petros, P. J. Hopkins, S. Spruill, G. Broadwater, J. J. Vredenburgh, O. M. Colvin, W. P. Peters, R. B. Jones, J. Hall, and J. R. Marks Associations Between Drug Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6117 - 6125. [Abstract] [Full Text] [PDF]

				W. P. Peters, G. L. Rosner, J. J. Vredenburgh, E. J. Shpall, M. Crump, P. G. Richardson, M. W. Schuster, L. B. Marks, C. Cirrincione, L. Norton, et al. Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13 J. Clin. Oncol., April 1, 2005; 23(10): 2191 - 2200. [Abstract] [Full Text] [PDF]

				M. E. de Jonge, A. D.R. Huitema, A. C. Tukker, S. M. van Dam, S. Rodenhuis, and J. H. Beijnen Accuracy, Feasibility, and Clinical Impact of Prospective Bayesian Pharmacokinetically Guided Dosing of Cyclophosphamide, Thiotepa, and Carboplatin in High-Dose Chemotherapy Clin. Cancer Res., January 1, 2005; 11(1): 273 - 282. [Abstract] [Full Text] [PDF]